Novamind Inc. trades on the FSE under the symbol HN2
Novamind ($NM | $NVMDF | $HN2) is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.
Novamind is focused on three pillars: Clinical care, clinical research and a retreat network
Hosted a pivotal ketamine study that led to the FDA-approval of SpravatoTM (the first, fast-acting drug for depression) by Janssen Pharmaceuticals
Currently contracted for 8 clinical trials
Key research site for Merck & Co.’s phase II clinical trial of MK-1942 for treatment-resistant depression
Will be evaluated as a research site for Bionomics’ phase II clinical trial of BNC210 for PTSD
Novamind is a strategic investor in Bionomics
Co-investors include: Apeiron, Biotech Value Fund, Merck, Mike Novogratz, and Peter Thiel
Research partners include:
iii. Retreat network
Novamind is building a network of psychedelic retreats in jurisdictions with established regulations for the use of psychedelics. It has strategic investments in the Netherlands-based Synthesis Institute and the Costa Rica-based Circadia Center
Synthesis was founded in 2018 and has hosted medically supervised psilocybin retreats for more than 600 participants
Circadia expects to host its first psychedelic retreat post COVID-19
GET THE HEADLINES + UPDATES
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.